PBK and neoplasm: The administration of TOPK inhibitor OTS514 enhanced the anticancer effect of 5‐FU in the in vivo tumorigenesis model, and the combinatory use of OTS514 and KRASG12C inhibitor AMG510 showed synergistic anti‐tumour effect.